Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Free Research Reports on BIDU, HEB, IDIX and YUM Issued by the Bedford Report

BIDU, AIM, YUM
Free Research Reports on BIDU, HEB, IDIX and YUM Issued by the Bedford Report
http://media.marketwire.com/attachments/201211/53317_equitynewscircuit-logo-final.jpghttp://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=982551&ProfileId=051205&sourceType=1

NEW YORK, NY -- (Marketwire) -- 02/06/13 -- The Bedford Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.

Baidu.com, Inc. (NASDAQ: BIDU) shares fell 10 percent on more than three-times the average daily volume Tuesday. Due to growing competition in the Chinese search engine market the company has forecasted total revenues to range between $945.4 million to $975.9 million for the first quarter of 2013.

Find out more about Baidu including full access to the free equity report at: www.BedfordReport.com/BIDU

Hemispherx BioPharma, Inc. (NYSE: HEB) shares declined 16 percent on nearly 6 million shares traded Tuesday. The company has reported that the FDA has declined to approve its new drug application for Ampligen for Chronic Fatigue Syndrome.

Find out more about Hemispherx BioPharma including full access to the free equity report at: www.BedfordReport.com/HEB

Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX) current focus is on the treatment of patients with hepatitis C infection. The company earlier this week reported has elected not to continue its clinical development program for IDX184, or to continue its development of IDX19368.

Find out more about Idenix Pharmaceuticals including full access to the free equity report at: www.BedfordReport.com/IDIX

Yum! Brands, Inc. (NYSE: YUM) shares declined 4 percent on over four-times the average daily volume Tuesday. For the first quarter the company forecasted a steep 25 percent drop in China's same-store sales. Sales in the region have been negatively impacted by an investigation by the Shanghai FDA into a former poultry supplier.

Find out more about Yum! Brands including full access to the free equity report at: www.BedfordReport.com/YUM

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein.

A third party, Providence Media Strategies LLC has paid Equity News Circuit five hundred dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.


Contact Information:
Equity News Circuit
Email Contact



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today